176 related articles for article (PubMed ID: 36364432)
21. Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer.
Martin M; Garcia-Saenz JA; Manso L; Llombart A; Cassinello A; Atienza M; Ringeisen F; Ciruelos E
Future Oncol; 2020 Nov; 16(33):2763-2778. PubMed ID: 32781837
[TBL] [Abstract][Full Text] [Related]
22. A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.
Chong QY; Kok ZH; Bui NL; Xiang X; Wong AL; Yong WP; Sethi G; Lobie PE; Wang L; Goh BC
Pharmacol Res; 2020 Jun; 156():104686. PubMed ID: 32068118
[TBL] [Abstract][Full Text] [Related]
23. Simultaneous determination of atenolol and amiloride in pharmaceutical preparations by capillary zone electrophoresis with capacitively coupled contactless conductivity detection.
Al Azzam KM; Saad B; Aboul-Enein HY
Biomed Chromatogr; 2010 Sep; 24(9):948-53. PubMed ID: 20082285
[TBL] [Abstract][Full Text] [Related]
24. Simultaneous determination of atenolol, chlorthalidone and amiloride in pharmaceutical preparations by capillary zone electrophoresis with ultraviolet detection.
Al Azzam KM; Saad B; Aboul-Enein HY
Biomed Chromatogr; 2010 Sep; 24(9):977-81. PubMed ID: 20066730
[TBL] [Abstract][Full Text] [Related]
25. CDK4-6 inhibitors in breast cancer: current status and future development.
Choo JR; Lee SC
Expert Opin Drug Metab Toxicol; 2018 Nov; 14(11):1123-1138. PubMed ID: 30360668
[TBL] [Abstract][Full Text] [Related]
26. A green capillary zone electrophoresis method for the simultaneous determination of piperacillin, tazobactam and cefepime in pharmaceutical formulations and human plasma.
Al-Attas A; Nasr JJ; El-Enany N; Belal F
Biomed Chromatogr; 2015 Dec; 29(12):1811-8. PubMed ID: 26058453
[TBL] [Abstract][Full Text] [Related]
27. The Cyclin-Dependent Kinase 4/6 Inhibitor Abemaciclib Is Tolerated Better than Palbociclib by Advanced Breast Cancer Patients with High Serum Albumin Levels.
Nakatsukasa H; Takahashi M; Takahashi K; Takashima T; Asano Y; Morisaki T; Kashiwagi S; Noda S; Nakamura Y
Biol Pharm Bull; 2022; 45(10):1476-1481. PubMed ID: 36184505
[TBL] [Abstract][Full Text] [Related]
28. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.
Groenland SL; Martínez-Chávez A; van Dongen MGJ; Beijnen JH; Schinkel AH; Huitema ADR; Steeghs N
Clin Pharmacokinet; 2020 Dec; 59(12):1501-1520. PubMed ID: 33029704
[TBL] [Abstract][Full Text] [Related]
29. Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer.
Tamura K
Jpn J Clin Oncol; 2019 Dec; 49(11):993-998. PubMed ID: 31665472
[TBL] [Abstract][Full Text] [Related]
30. Intestinal Toxicity in Rats Following Administration of CDK4/6 Inhibitors Is Independent of Primary Pharmacology.
Thibault S; Hu W; Hirakawa B; Kalabat D; Franks T; Sung T; Khoh-Reiter S; Lu S; Finkelstein M; Jessen B; Sacaan A
Mol Cancer Ther; 2019 Feb; 18(2):257-266. PubMed ID: 30401694
[TBL] [Abstract][Full Text] [Related]
31. CDK4/6 blockade in breast cancer: current experience and future perspectives.
Zardavas D; Pondé N; Tryfonidis K
Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
[TBL] [Abstract][Full Text] [Related]
32. Abemaciclib sensitizes HPV-negative cervical cancer to chemotherapy via specifically suppressing CDK4/6-Rb-E2F and mTOR pathways.
Liu Y; Zhao R; Fang S; Li Q; Jin Y; Liu B
Fundam Clin Pharmacol; 2021 Feb; 35(1):156-164. PubMed ID: 32446293
[TBL] [Abstract][Full Text] [Related]
33. Development and Validation of a Quantitative LC-MS/MS Method for CDK4/6 Inhibitors Palbociclib, Ribociclib, Abemaciclib, and Abemaciclib-M2 in Human Plasma.
Burke SM; Kamal M; Goey AKL
Ther Drug Monit; 2023 Jun; 45(3):327-336. PubMed ID: 36728357
[TBL] [Abstract][Full Text] [Related]
34. Simultaneous determination of ofloxacin and ornidazole in pharmaceutical preparations by capillary zone electrophoresis.
See KL; Elbashir AA; Saad B; Ali AS; Aboul-Enein HY
Biomed Chromatogr; 2009 Dec; 23(12):1283-90. PubMed ID: 19488980
[TBL] [Abstract][Full Text] [Related]
35. Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation.
Torres-Guzmán R; Ganado MP; Mur C; Marugan C; Baquero C; Yang Y; Zeng Y; Bian H; Du J; de Dios A; Puig O; Lallena MJ
Oncotarget; 2022; 13():864-875. PubMed ID: 35813283
[TBL] [Abstract][Full Text] [Related]
36. Optimisation, validation and application of a capillary electrophoretic method for the determination of zafirlukast in pharmaceutical formulations.
Süslü I; Demircan S; Altinöz S; Kir S
J Pharm Biomed Anal; 2007 May; 44(1):16-22. PubMed ID: 17320335
[TBL] [Abstract][Full Text] [Related]
37. Abemaciclib, a third CDK 4/6 inhibitor for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer.
El Hachem G; Gombos A; Awada A
Expert Rev Anticancer Ther; 2021 Jan; 21(1):81-92. PubMed ID: 33054442
[TBL] [Abstract][Full Text] [Related]
38. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
O'Sullivan CC
Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
[TBL] [Abstract][Full Text] [Related]
39. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
40. CDK4/6 inhibitors downregulate the ubiquitin-conjugating enzymes UBE2C/S/T involved in the ubiquitin-proteasome pathway in ER + breast cancer.
Lin CY; Yu CJ; Liu CY; Chao TC; Huang CC; Tseng LM; Lai JI
Clin Transl Oncol; 2022 Nov; 24(11):2120-2135. PubMed ID: 35917055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
